NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its novel treatment of the debilitating bowel disease.
The recent guidelines suggest risk management within the existing framework of laws under the guiding principle of ‘Do No ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback